EP2924127A1 — Method and kit for prognosis of OPA1 gene induced diseases, e.g. Kjers optic atrophy.
Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2015-09-30 · 11y expired
What this patent protects
The present invention provides the use of Nuclear factor (erythroid-derived 2)-like 2 (NRF2)-activated genes products, e.g. SOD1. CAT and ACO2 in the prognosis of an OPA1 gene- or OPA1 gene product- deficit-induced disease, or related complications, e.g. optic atrophy and optic n…
USPTO Abstract
The present invention provides the use of Nuclear factor (erythroid-derived 2)-like 2 (NRF2)-activated genes products, e.g. SOD1. CAT and ACO2 in the prognosis of an OPA1 gene- or OPA1 gene product- deficit-induced disease, or related complications, e.g. optic atrophy and optic neuropathy, in a biological sample selected from fibroblasts, epithelial cells, blood samples or a mixture thereof, of a patient affected or suspected to be affected by said disease.
Drugs covered by this patent
- Tecfidera (DIMETHYL FUMARATE) · Biogen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.